Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: Measuring trends in HIV pre-exposure prophylaxis (HIV-PrEP) uptake is important to inform planning for prevention programs and policies. The HIV-PrEP-to-need ratio (PnR) is a construct used by public health organizations to explore disparities in the provision of HIV-PrEP across geographic areas and demographic categories (e.g., age, sex).

Methods: This is a retrospective database review study using administrative pharmacy data, containing limited demographic information, from nine Canadian provinces. Annual estimates of persons taking HIV-PrEP and PnR were generated using data from the company IQVIA and the BC Centre for Excellence on HIV/AIDS. Data on new HIV diagnoses were obtained from the National HIV Surveillance System. The PnR was defined as the number of HIV-PrEP users divided by the number of new HIV diagnoses annually and is interpreted as the number of HIV-negative people using HIV-PrEP each year for every person newly diagnosed with HIV.

Results: In 2021, an estimated 23,644 individuals were prescribed HIV-PrEP, corresponding to an HIV-PrEP prevalence of 66.9 per 100,000 persons. This represents a 1.8-fold increase since 2018. The overall PnR was 16.8, meaning that for every person newly diagnosed with HIV, 17 HIV-negative individuals were taking HIV-PrEP. There were disparities between provinces (PnR range: 1.5/100,000-37.7/100,000) and between males and females (PnR 22.6 and 1.2, respectively). Females, individuals aged 0-19 years, and those in Manitoba, Saskatchewan and Prince Edward Island, had lower levels of HIV-PrEP use relative to epidemic need.

Conclusion: In Canada, the use of HIV-PrEP increased from 2018 to 2021 and uptake varied by age, sex and province. HIV-PrEP-to-need ratio is a useful measure to assess uptake of HIV-PrEP as a prevention strategy and could be used to explore disparities in provision across provinces and available demographic categories. However, PnR could be improved with more information on key populations and other attributes, such as race/ethnicity, socioeconomic status and residence of city/rural area.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11709143PMC
http://dx.doi.org/10.14745/ccdr.v51i01a05DOI Listing

Publication Analysis

Top Keywords

hiv-prep
12
hiv-prep-to-need ratio
12
hiv pre-exposure
8
pre-exposure prophylaxis
8
prophylaxis hiv-prep
8
canadian provinces
8
explore disparities
8
disparities provision
8
demographic categories
8
hiv diagnoses
8

Similar Publications

We developed and implemented a PrEP navigation program ("SNAPS") in a NYC safety-net hospital with the objectives to co-locate navigation, clinical PrEP services, and payment assistance. Adherence and retention to PrEP-related care were assessed by mean medication possession ratios (MPRs) and number of appointments over 12 months. Compared to the pre-SNAPS cohort, the post-SNAPS cohort was less likely to be cisgender male (64.

View Article and Find Full Text PDF

Chemsex and sexual risk behavior among MSM on PrEP in Stockholm, Sweden.

Drug Alcohol Depend Rep

September 2025

Division of Social Work, Department of Behavior, Law and Social Science, Örebro University, Sweden.

Background: Chemsex, typically defined as the use of specific psychoactive substances to enhance sexual experiences, has been linked to increased sexual health risks among men who have sex with men (MSM). This study examines frequency of chemsex use and associations between chemsex, risk-taking, and sexual practices among MSM on pre-exposure prophylaxis against HIV (PrEP) attending Sweden's largest sexual health clinic.

Methods: A survey among MSM on PrEP (n = 290) mapped demographics, sexualized drug use, sexual practices, and alcohol use at Venhälsan, (South General Hospital), Stockholm, Sweden.

View Article and Find Full Text PDF

Ultra-long-acting injectable, biodegradable, and removable in-situ forming implant with cabotegravir for HIV prevention.

J Control Release

August 2025

Lampe Joint Department of Biomedical Engineering, North Carolina State University and The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Division of Pharmacoengineering and Molecular Pharmaceutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chap

HIV is a global health issue affecting approximately 40 million people worldwide, with low patient adherence being the primary challenge for maintaining effective pre-exposure prophylaxis (PrEP). Limitations of oral PrEP are mainly attributed to lack of adherence due to pill fatigue or stigma [1, 2]. Recently introduced long-acting injectables offer several advantages over daily PrEP, namely by improving adherence and improving efficacy [3-5].

View Article and Find Full Text PDF

BackgroundHIV-PrEP is a key component of HIV combination prevention and has been routinely available through oral formulations (i.e. oral tablets) across sexual health services (SHSs) in the UK since 2020.

View Article and Find Full Text PDF

Tenofovir to Prevent HIV Infection in Western China: Pragmatic Randomized Controlled Trial.

JMIR Public Health Surveill

August 2025

School of Public Health, Chongqing Medical University, Yixue Rd1#, Yuzhong district, Chongqing, 400016, China, 86 13508312469.

Background: Pre-exposure prophylaxis (PrEP) programs have been implemented in multiple countries. Evidence from clinical trials and cohort studies has proven the safety and effectiveness of PrEP. However, minimizing drug-related adverse effects and cost should be primarily considered in PrEP.

View Article and Find Full Text PDF